Immuron Ltd — Capital/Financing Update 2011

Feb 28, 2011

==> picture [193 x 42] intentionally omitted <==

ASX Release

1 March 2011

Immuron Limited ABN 80 063 114 045

Immuron Granted Key Patent for Anti-influenza Product

Corporate Details:

ASX Code: IMC

Directors

Chairman:

Prof Colin Chapman

Non-Executive Directors: Prof Roy Robins-Browne Mr Simon Sallka Dr Elane Zelcer

Chief Executive Officer

Joe Baini

Chief Scientific Officer Dr Grant Rawlin

Medical Director

Prof Yaron Ilan

• Issued Australian patent for anti-Influenza product to 2028

• Endorses Immuron’s pursuit of global patent coverage

Melbourne Australia 1 March 2011 – Melbourne-based clinical stage biopharmaceutical company Immuron Limited has been granted the Australian patent for its influenza preventative product candidate (Imm-255).

Immuron’s influenza product will potentially be the world’s first orally administered product for mucosal protection against influenza viruses. The safety profile of this product emanating from Immuron’s platform technology allows for the potential acceleration to market.

The patent, granted by the Australian Patents Office, contains claims for treatment and inhibition of influenza infection by applying anti-influenza antibodies to oral and respiratory surfaces.

Immuron’s antibody approach may provide a broader protection against Influenza viruses since it is designed to cope with rapidly changing strains as viruses evolve.

The patent provides protection through to the year 2028 and is an important part of Immuron’s objective to maintain proprietary value for its influenza program. This patent term, coupled with the safety profile may result in many years of patent protection during the commercialisation phase of the product.

Substantial Shareholder

Hadasit Medical Research 17.9%

ENDS

About Immuron Limited

Immuron Limited Level 1 39 Leveson Street North Melbourne VIC 3051 Australia

Tel: +61 (0)3 9018 4880 www.immuron.com

Immuron is a biopharmaceutical company focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans. Immuron is a uniquely positioned biotechnology company with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as type II diabetes and fatty liver (NASH), and the prevention of influenza.

Immuron has one product in the market, Travelan, for use in preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and the Universities of Melbourne and Monash (Australia).

Enquiries

Joe Baini – Chief Executive Officer Immuron Ltd +61 3 9018 4880 joe@immuron.com

Media Relations:

Emma Power Monsoon Communications 61 3 9620 3333 or 61 (0)419 149 525